Enterone

Enterome is a clinical-stage biopharmaceutical company based in Paris, France, pioneering the development of novel drugs based on the microbiome-immunology axis. The company utilizes its proprietary Mimicry platform to identify bacterial peptides from the gut microbiome that mimic human antigens, triggering targeted immune responses. Its primary focus is on "OncoMimics," a pipeline of therapeutic vaccines for cancer, and "EndoMimics," targeting inflammatory and autoimmune diseases. The lead candidate, EO2401, is currently in Phase 2 clinical trials for recurrent glioblastoma and adrenal tumors. Enterome has secured significant partnerships with industry leaders like Takeda and Nestlé Health Science to advance its innovative therapeutic programs.